Search Results

There are 12254 results for: content related to: Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

  1. Treatment of chronic hepatitis B

    Journal of Viral Hepatitis

    Volume 12, Issue 4, July 2005, Pages: 333–345, P. Marcellin, T. Asselah and N. Boyer

    Article first published online : 28 JUN 2005, DOI: 10.1111/j.1365-2893.2005.00599.x

  2. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis

    Journal of Viral Hepatitis

    Volume 15, Issue 2, February 2008, Pages: 89–102, L. H. Katz, A. Fraser, A. Gafter-Gvili, L. Leibovici and R. Tur-Kaspa

    Article first published online : 24 SEP 2007, DOI: 10.1111/j.1365-2893.2007.00902.x

  3. You have full text access to this OnlineOpen article
    The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore

    Journal of Viral Hepatitis

    Volume 14, Issue 11, November 2007, Pages: 751–766, L. F. Lacey and E. Gane

    Article first published online : 27 APR 2007, DOI: 10.1111/j.1365-2893.2007.00865.x

  4. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir

    Journal of Viral Hepatitis

    Volume 18, Issue 10, October 2011, Pages: e432–e438, M. S. Kwak, J. W. Choi, J. S. Lee, K. A. Kim, J. H. Suh, Y. S. Cho, S. Y. Won, B. K. Park and C. K. Lee

    Article first published online : 13 MAY 2011, DOI: 10.1111/j.1365-2893.2011.01461.x

  5. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B

    Journal of Viral Hepatitis

    Volume 12, Issue 4, July 2005, Pages: 393–397, J. W. Shin, N. H. Park, J. H. Park, J. H. Park, I. D. Jeong, S-J. Bang, K. R. Joo and D. H. Kim

    Article first published online : 14 MAR 2005, DOI: 10.1111/j.1365-2893.2005.00606.x

  6. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance

    Journal of Viral Hepatitis

    Volume 12, Issue 4, July 2005, Pages: 398–404, D. N. Moskovitz, C. Osiowy, E. Giles, G. Tomlinson and E. J. Heathcote

    Article first published online : 26 APR 2005, DOI: 10.1111/j.1365-2893.2005.00613.x

  7. Mechanism of restoration of immune responses of patients with chronic hepatitis B during lamivudine therapy: increased antigen processing and presentation by dendritic cells

    Journal of Viral Hepatitis

    Volume 18, Issue 3, March 2011, Pages: 200–205, S. M. F. Akbar, N. Horiike, S. Chen, K. Michitaka, M. Abe, Y. Hiasa, B. Matsuura and M. Onji

    Article first published online : 28 MAR 2010, DOI: 10.1111/j.1365-2893.2010.01300.x

  8. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine

    Journal of Viral Hepatitis

    Volume 10, Issue 4, July 2003, Pages: 256–265, A. M. Bozdayi̇, Ö. Uzunalimoğlu, A. R. Türkyi̇lmaz, N. Aslan, O. Sezgin, T. Sahin, G. Bozdayi̇, K. Çi̇nar, S. B. Pai, R. Pai, H. Bozkaya, S. Karayalçi̇n, C. Yurdaydi̇n and R. F. Schinazi

    Article first published online : 23 JUN 2003, DOI: 10.1046/j.1365-2893.2003.00435.x

  9. Differentially expressed cellular genes following HBV: potential targets of anti-HBV drugs?

    Journal of Viral Hepatitis

    Volume 12, Issue 4, July 2005, Pages: 357–363, J. Yang, X. C. Bo, J. Yao, N. M. Yang and S. Q. Wang

    Article first published online : 3 MAY 2005, DOI: 10.1111/j.1365-2893.2005.00611.x

  10. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

    Journal of Viral Hepatitis

    Volume 14, Issue 11, November 2007, Pages: 767–774, X. P. Pan, L. J. Li, W. B. Du, M. W. Li, H. C. Cao and J. F. Sheng

    Article first published online : 15 APR 2007, DOI: 10.1111/j.1365-2893.2007.00869.x

  11. Application of allele-specific RNAi in hepatitis B virus lamivudine resistance

    Journal of Viral Hepatitis

    Volume 18, Issue 10, October 2011, Pages: e491–e498, X. Teng, J.-Y. Liu, D. Li, Y. Fang, X.-Y. Wang, Y.-X. Ma, S.-J. Chen, Y.-X. Zhao, W.-Z. Xu and H.-X. Gu

    Article first published online : 7 JUL 2011, DOI: 10.1111/j.1365-2893.2011.01483.x

  12. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B

    Journal of Viral Hepatitis

    Volume 8, Issue 4, July 2001, Pages: 270–275, M. Buti, M. Cotrina, R. Jardi, E. Cruz De Castro, F. Rodriguez-Frias, F. Sánchez-Avila, R. Esteban and J. Guardia

    Article first published online : 21 DEC 2001, DOI: 10.1046/j.1365-2893.2001.00296.x

  13. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B

    Journal of Viral Hepatitis

    Volume 11, Issue 5, September 2004, Pages: 432–438, S. K. Fung, F. Wong, M. Hussain and A. S. F. Lok

    Article first published online : 9 SEP 2004, DOI: 10.1111/j.1365-2893.2004.00556.x

  14. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

    Journal of Viral Hepatitis

    Volume 9, Issue 3, May 2002, Pages: 208–212, K. M. Lee, S. W. Cho, S. W. Kim, H. J. Kim, K. B. Hahm and J. H. Kim

    Article first published online : 9 MAY 2002, DOI: 10.1046/j.1365-2893.2002.00357.x

  15. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?

    Journal of Viral Hepatitis

    Volume 9, Issue 3, May 2002, Pages: 221–228, A. B. Van Nunen, R. A. De Man, R. A. Heijtink, A. C. T. M. Vossen and S. W. Schalm

    Article first published online : 9 MAY 2002, DOI: 10.1046/j.1365-2893.2002.00337.x

  16. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA

    Journal of Viral Hepatitis

    Volume 9, Issue 6, November 2002, Pages: 411–418, D. V. Morrissey, P. A. Lee, D. A. Johnson, S. L. Overly, J. A. McSwiggen, L. Beigelman, V. R. Mokler, L. Maloney, C. Vargeese, K. Bowman, J. T. O'Brien, C. S. Shaffer, A. Conrad, P. Schmid, J. D. Morrey, D. G. Macejak, P. A. Pavco and L. M. Blatt

    Article first published online : 13 NOV 2002, DOI: 10.1046/j.1365-2893.2002.00383.x

  17. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy

    Journal of Viral Hepatitis

    Volume 19, Issue 8, August 2012, Pages: 581–593, F.-Q. Yang, Y.-Y. Yu, G.-Q. Wang, J. Chen, J.-H. Li, Y.-Q. Li, G.-R. Rao, G.-Y. Mo, X.-R. Luo and G.-M. Chen

    Article first published online : 26 FEB 2012, DOI: 10.1111/j.1365-2893.2012.01589.x

  18. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine

    Journal of Viral Hepatitis

    Volume 13, Issue 6, June 2006, Pages: 415–425, J. Gotto, G. J. M. Webster, D. Brown, J. Jenkins, G. M. Dusheiko and A. Bertoletti

    Article first published online : 8 MAR 2006, DOI: 10.1111/j.1365-2893.2005.00716.x

  19. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication

    Journal of Viral Hepatitis

    Volume 13, Issue 3, March 2006, Pages: 158–165, J. Yang, X. C. Bo, X. R. Ding, J. M. Dai, M. L. Zhang, X. H. Wang and S. Q. Wang

    Article first published online : 29 SEP 2005, DOI: 10.1111/j.1365-2893.2005.00666.x

  20. Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B

    Journal of Viral Hepatitis

    Volume 12, Issue 2, March 2005, Pages: 216–221, N. H. Park, J. W. Shin, J. H. Park, S-J. Bang, D-H. Kim, K. R. Joo and D. H. Kim

    Article first published online : 17 FEB 2005, DOI: 10.1111/j.1365-2893.2005.00602.x